JPMorgan Chase & Co. Acquires 193,124 Shares of HilleVax, Inc. (NASDAQ:HLVX)

JPMorgan Chase & Co. lifted its holdings in HilleVax, Inc. (NASDAQ:HLVX) by 1,376.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 207,151 shares of the company’s stock after acquiring an additional 193,124 shares during the period. JPMorgan Chase & Co. owned 0.42% of HilleVax worth $429,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. SG Americas Securities LLC increased its holdings in HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after acquiring an additional 6,916 shares during the last quarter. Ieq Capital LLC increased its holdings in shares of HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after purchasing an additional 9,344 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of HilleVax in the fourth quarter worth about $26,000. Barclays PLC boosted its stake in HilleVax by 255.6% during the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock valued at $74,000 after buying an additional 30,213 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in HilleVax by 81.7% during the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock valued at $139,000 after buying an additional 35,546 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company’s stock.

HilleVax Price Performance

Shares of HLVX stock opened at $1.93 on Friday. The company has a market cap of $96.77 million, a PE ratio of -0.62 and a beta of 0.86. HilleVax, Inc. has a 1 year low of $1.34 and a 1 year high of $16.31. The stock’s 50 day simple moving average is $1.69 and its two-hundred day simple moving average is $1.84.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Equities research analysts expect that HilleVax, Inc. will post -2.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and set a $2.00 target price on shares of HilleVax in a research report on Monday, March 31st. Six investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.